332 related articles for article (PubMed ID: 34883407)
1. Use of long-acting injectable antiretroviral agents for human immunodeficiency Virus: A review.
Ariyo OE; Jones CE
J Clin Virol; 2022 Jan; 146():105032. PubMed ID: 34883407
[TBL] [Abstract][Full Text] [Related]
2. The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis.
Phillips AN; Bansi-Matharu L; Cambiano V; Ehrenkranz P; Serenata C; Venter F; Pett S; Flexner C; Jahn A; Revill P; Garnett GP
Lancet Glob Health; 2021 May; 9(5):e620-e627. PubMed ID: 33770513
[TBL] [Abstract][Full Text] [Related]
3. Contribution of cabotegravir + rilpivirine long-acting for the treatment of HIV-1 infection.
Calleja-Hernández MÁ; Martinez-Sesmero JM; Vallejo-Aparicio LA; Hernández-Novoa B; Badia X
Farm Hosp; 2022 Jul; 46(4):208-214. PubMed ID: 36183218
[TBL] [Abstract][Full Text] [Related]
4. Long-acting Injectable Cabotegravir/Rilpivirine Effective in a Small Patient Cohort With Virologic Failure on Oral Antiretroviral Therapy.
Brock JB; Herrington P; Hickman M; Hickman A
Clin Infect Dis; 2024 Jan; 78(1):122-124. PubMed ID: 37740255
[TBL] [Abstract][Full Text] [Related]
5. Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study.
Lowenthal ED; Chapman J; Ohrenschall R; Calabrese K; Baltrusaitis K; Heckman B; Yin DE; Agwu AL; Harrington C; Van Solingen-Ristea RM; McCoig CC; Adeyeye A; Kneebone J; Chounta V; Smith-Anderson C; Camacho-Gonzalez A; D'Angelo J; Bearden A; Crauwels H; Huang J; Buisson S; Milligan R; Ward S; Bolton-Moore C; Gaur AH; ;
Lancet HIV; 2024 Apr; 11(4):e222-e232. PubMed ID: 38538161
[TBL] [Abstract][Full Text] [Related]
6. Acceptance Rate and Reasons for Rejection of Long Acting Injectable Antiretrovirals.
Feihel D; Spier D; Stevens T; Stefanov DG; Ahmadi L
AIDS Behav; 2023 Jul; 27(7):2370-2375. PubMed ID: 36576664
[TBL] [Abstract][Full Text] [Related]
7. Monthly injectable cabotegravir/rilpivirine to manage HIV infection in adults.
Blackwell CW; López Castillo H
J Am Assoc Nurse Pract; 2022 Jul; 34(7):918-923. PubMed ID: 35580282
[TBL] [Abstract][Full Text] [Related]
8. Compassionate use of long-acting cabotegravir plus rilpivirine for people living with HIV-1 in need of parenteral antiretroviral therapy.
D'Amico R; Cenoz Gomis S; Moodley R; Van Solingen-Ristea R; Baugh B; Van Landuyt E; Van Eygen V; Min S; Cutrell A; Foster C; Chilton D; Allard SD; Ruiter A
HIV Med; 2023 Feb; 24(2):202-211. PubMed ID: 35945163
[TBL] [Abstract][Full Text] [Related]
9. Long-acting antiretrovirals and HIV treatment adherence.
Nachega JB; Scarsi KK; Gandhi M; Scott RK; Mofenson LM; Archary M; Nachman S; Decloedt E; Geng EH; Wilson L; Rawat A; Mellors JW
Lancet HIV; 2023 May; 10(5):e332-e342. PubMed ID: 37062293
[TBL] [Abstract][Full Text] [Related]
10. Cabotegravir/Rilpivirine: the last FDA-approved drug to treat HIV.
Taki E; Soleimani F; Asadi A; Ghahramanpour H; Namvar A; Heidary M
Expert Rev Anti Infect Ther; 2022 Aug; 20(8):1135-1147. PubMed ID: 35596583
[TBL] [Abstract][Full Text] [Related]
11. Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine.
Patel P; Teichner P; Elliot E; Boffito M; Murray M; Polli JW; Baker M; Ford SL; Han K; Russu A; Crauwels H; D'Amico RD; Spreen WR; van Wyk J
Ther Adv Infect Dis; 2023; 10():20499361231214626. PubMed ID: 38107552
[TBL] [Abstract][Full Text] [Related]
12. Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
Orkin C; Arasteh K; Górgolas Hernández-Mora M; Pokrovsky V; Overton ET; Girard PM; Oka S; Walmsley S; Bettacchi C; Brinson C; Philibert P; Lombaard J; St Clair M; Crauwels H; Ford SL; Patel P; Chounta V; D'Amico R; Vanveggel S; Dorey D; Cutrell A; Griffith S; Margolis DA; Williams PE; Parys W; Smith KY; Spreen WR
N Engl J Med; 2020 Mar; 382(12):1124-1135. PubMed ID: 32130806
[TBL] [Abstract][Full Text] [Related]
13. The Promise of Improved Adherence With Long-Acting Antiretroviral Therapy: What Are the Data?
Scarsi KK; Swindells S
J Int Assoc Provid AIDS Care; 2021; 20():23259582211009011. PubMed ID: 33902356
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of a multiplex UHPLC-MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV.
Courlet P; Alves Saldanha S; Cavassini M; Marzolini C; Choong E; Csajka C; Günthard HF; André P; Buclin T; Desfontaine V; Decosterd LA
J Mass Spectrom; 2020 Jun; 55(6):e4506. PubMed ID: 32160389
[TBL] [Abstract][Full Text] [Related]
15. Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain.
Moreno S; Rivero A; Ventayol P; Falcó V; Torralba M; Schroeder M; Neches V; Vallejo-Aparicio LA; Mackenzie I; Turner M; Harrison C
Infect Dis Ther; 2023 Aug; 12(8):2039-2055. PubMed ID: 37452174
[TBL] [Abstract][Full Text] [Related]
16. Human Immunodeficiency Virus Type 1 RNA Levels in Rectal and Seminal Compartments After Switching to Long-Acting Cabotegravir Plus Rilpivirine: A Longitudinal Study.
Masiá M; Fernández-González M; Agulló V; Mascarell P; Padilla S; García-Abellán J; Gutiérrez F
Clin Infect Dis; 2023 Feb; 76(3):e748-e751. PubMed ID: 35986671
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and Drug-Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine.
Hodge D; Back DJ; Gibbons S; Khoo SH; Marzolini C
Clin Pharmacokinet; 2021 Jul; 60(7):835-853. PubMed ID: 33830459
[TBL] [Abstract][Full Text] [Related]
18. Long-Acting Antiretroviral Drug Therapy in Adolescents: Current Status and Future Prospects.
Freij BJ; Aldrich AM; Ogrin SL; Olivero RM
J Pediatric Infect Dis Soc; 2023 Feb; 12(1):43-48. PubMed ID: 36525377
[TBL] [Abstract][Full Text] [Related]
19. Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).
Chounta V; Overton ET; Mills A; Swindells S; Benn PD; Vanveggel S; van Solingen-Ristea R; Wang Y; Hudson KJ; Shaefer MS; Margolis DA; Smith KY; Spreen WR
Patient; 2021 Nov; 14(6):849-862. PubMed ID: 34056699
[TBL] [Abstract][Full Text] [Related]
20. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.
Margolis DA; Brinson CC; Smith GHR; de Vente J; Hagins DP; Eron JJ; Griffith SK; Clair MHS; Stevens MC; Williams PE; Ford SL; Stancil BS; Bomar MM; Hudson KJ; Smith KY; Spreen WR;
Lancet Infect Dis; 2015 Oct; 15(10):1145-1155. PubMed ID: 26201299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
